You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-HER2 Antibody Drug Conjugate (ADC)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Breast Tumors Trial in France (DS-8201a)

Active, not recruiting
  • Breast Tumors
  • Angers, France
  • +20 more
Feb 1, 2022

Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer Trial in Australia (IKS014)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Concord, New South Wales, Australia
  • +4 more
May 30, 2023

Salivary Gland Tumors Trial in Beijing (RC48-ADC)

Recruiting
  • Salivary Gland Tumors
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 28, 2022

Metastatic Breast Cancer Trial in Villejuif (U3-1402)

Recruiting
  • Metastatic Breast Cancer
  • Villejuif, France
    Gustave Roussy
Jul 7, 2021

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Withdrawn
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Jan 24, 2023

Light Chain (AL) Amyloidosis Trial (STI-6129)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • (no location specified)
Jan 11, 2023

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma Trial in Beijing (RC48-ADC)

Completed
  • Gastric Cancer
  • HER2 Overexpressing Gastric Carcinoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jan 12, 2022

Light Chain (AL) Amyloidosis Trial in New York (STI-6129)

Recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • Duarte, California
  • +3 more
Jan 12, 2023

Gynecological Malignancy Trial in Beijing (RC48-ADC)

Recruiting
  • Gynecological Malignancy
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences Cancer Hospital
Jan 6, 2022

Melanoma, Stage II, HER2-positive, Advanced Melanoma Trial (RC48-ADC)

Not yet recruiting
  • Melanoma, Stage II
  • +2 more
  • (no location specified)
Nov 29, 2021

Breast Cancer, Non-small Cell Lung Carcinoma Trial in Worldwide (Trastuzumab deruxtecan (DS-8201a), Pembrolizumab)

Recruiting
  • Breast Cancer
  • Non-small Cell Lung Carcinoma
  • San Francisco, California
  • +24 more
Nov 30, 2022

Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)

Active, not recruiting
  • Breast Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 11, 2023

Urothelial Carcinoma Trial in Beijing (RC48-ADC)

Active, not recruiting
  • Urothelial Carcinoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 14, 2021

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

Urothelial Carcinoma Trial in China (RC48-ADC)

Active, not recruiting
  • Urothelial Carcinoma
  • Hefei, Anhui, China
  • +7 more
Feb 20, 2022

Solid Tumor Trial in Belgium, Netherlands, United Kingdom (SYD985 + Niraparib)

Active, not recruiting
  • Solid Tumor
  • SYD985 + Niraparib
  • Antwerp, Belgium
  • +5 more
Jan 23, 2023

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

HER2 Mutation-Related Tumors, HER2 Amplification Trial (ARX788)

Not yet recruiting
  • HER2 Mutation-Related Tumors
  • HER2 Amplification
  • (no location specified)
Aug 23, 2021

Breast Tumors Trial in Guangzhou (procedure, drug, biological)

Recruiting
  • Breast Neoplasms
  • Surgery for harvesting tumor-draining lymph nodes
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 2, 2023

Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • STI-6129
  • Beijing, Beijing, China
  • +3 more
Jan 9, 2023

Metastatic Solid Tumors, Esophageal Cancer, NSCLC Trial in Houston, San Antonio, Toronto (M1231)

Recruiting
  • Metastatic Solid Tumors
  • +2 more
  • Houston, Texas
  • +2 more
Jul 29, 2022

Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting

Recruiting
  • Breast Neoplasms
  • Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jul 30, 2022

Advanced Solid Tumors Trial in Tianjin (KM501)

Not yet recruiting
  • Advanced Solid Tumors
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Apr 5, 2023